Company

Hansa Biopharma AB

Headquarters: Lund, Sweden

Employees: 133

CEO: Mr. Søren Tulstrup

OMX: HNSA

Market Cap

kr3.39 Billion

SEK as of July 1, 2024

US$319.2 Million

Market Cap History

Hansa Biopharma AB market capitalization over time

Evolution of Hansa Biopharma AB market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Hansa Biopharma AB

Detailed Description

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Hansa Biopharma AB has the following listings and related stock indices.


Stock: OMX: HNSA wb_incandescent

Stock: FSX: 24H wb_incandescent

Details

Headquarters:

Scheelevägen 22

Lund, 222 63

Sweden

Phone: 46 46 16 56 70

Fax: 46 46 12 77 75